Key result
An essential triple-arginine motif in the amino-terminal domain and protein oligomerization are required for HIV-1 inhibition by human MX2.
A triple-arginine motif and protein oligomerization are essential for the HIV-1 resistance factor MX2 to exert its antiviral activity.
We have employed molecular genetic approaches to understand the domain organization of the HIV-1 resistance factor myxovirus resistance 2 (MX2). First, we describe an essential triple-arginine motif in the amino-terminal domain. Second, we demonstrate that this 91-residue domain mediates antiviral activity when appended to heterologous proteins, and we provide genetic evidence that protein oligomerization is required for MX2 function. These insights will facilitate future work aiming to elucidate MX2's mechanism of action.
No takes yet. Share an insight, caveat, or question.
Goujon et al. (2015) studied HIV-1. Human MX2 was evaluated on HIV-1 inhibition. An essential triple-arginine motif in the amino-terminal domain and protein oligomerization are required for HIV-1 inhibition by human MX2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: